Parathyroid hormone (PTH) has been approved by the US Food and Drug Administration (FDA) since 2002, when teriparatide, a 34–amino acid analog of PTH, was accepted for the treatment of osteoporosis. This evidence concerns the gene PTH and osteoporosis.